GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » WDB coco Co Ltd (TSE:7079) » Definitions » Forward PE Ratio

WDB coco Co (TSE:7079) Forward PE Ratio : 0.00 (As of Jun. 08, 2024)


View and export this data going back to 2019. Start your Free Trial

What is WDB coco Co Forward PE Ratio?

WDB coco Co's Forward PE Ratio for today is 0.00.

WDB coco Co's PE Ratio without NRI for today is 10.73.

WDB coco Co's PE Ratio for today is 10.73.


WDB coco Co Forward PE Ratio Historical Data

The historical data trend for WDB coco Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WDB coco Co Forward PE Ratio Chart

WDB coco Co Annual Data
Trend
Forward PE Ratio

WDB coco Co Quarterly Data
Forward PE Ratio

Competitive Comparison of WDB coco Co's Forward PE Ratio

For the Health Information Services subindustry, WDB coco Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WDB coco Co's Forward PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, WDB coco Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where WDB coco Co's Forward PE Ratio falls into.



WDB coco Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


WDB coco Co  (TSE:7079) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


WDB coco Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of WDB coco Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


WDB coco Co (TSE:7079) Business Description

Traded in Other Exchanges
N/A
Address
1-8-11 Harumi, Chuo-ku, Triton Square Y 27th Floor, Tokyo, JPN, 104-6127
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC related work, PMS facility contract support related work, clinical research support / monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments such as monitoring, safety information, data management and statistical analysis. It provides support for the development of generic drugs such as bioequivalence studies and biosimilars, clinical research and physician-led clinical trials.

WDB coco Co (TSE:7079) Headlines

No Headlines